<DOC>
	<DOCNO>NCT01650194</DOCNO>
	<brief_summary>The purpose study explore safety tolerability enzalutamide combination abiraterone acetate plus prednisone . Subjects diagnose cancer prostate get bad spread bone despite receive hormone treatment enrol receive study treatment disease progression .</brief_summary>
	<brief_title>A Study Determine Safety Tolerability Enzalutamide ( MDV3100 ) Combination With Abiraterone Acetate Bone Metastatic Castration-Resistant Prostate Cancer Patients</brief_title>
	<detailed_description>For study duration , subject maintain androgen deprivation gonadotropin release hormone ( GnRH ) agonist antagonist orchiectomy . Study drug administer disease progression . Disease progression define composite endpoint consist either clinical deterioration , radiographic progression prostate-specific antigen ( PSA ) progression accord Prostate Cancer Clinical Trials Working Group 2 ( PCWG2 ) criterion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature Presence metastatic disease bone Ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue orchiectomy ( i.e. , surgical medical castration ) Subject receive bisphosphonate denosumab therapy must stable dos least 4 week prior Day 1 Progressive disease define one follow three criterion ( Note : subject receive antiandrogen must demonstrate disease progression follow discontinuation antiandrogen ) : PSA progression define minimum two rise PSA level interval ≥ 1 week determination . The PSA value Screening visit ≥ 2 ng/mL Soft tissue disease progression define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Bone disease progression define PCWG2 criterion ( two new lesion bone scan compare prior scan ) Subject previously treat chemotherapy must two prior chemotherapy regimens treatment metastatic prostate cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Agree use doublebarrier method contraception involve use condom combination one following : contraceptive sponge , diaphragm , cervical ring spermicidal gel foam , sex woman childbearing potential length study one week abiraterone discontinue least three month enzalutamide discontinue Subject agrees participate another interventional study treatment Known suspect metastasis brain Absolute neutrophil count &lt; 1,000/μL , platelet count &lt; 75,000/μL , hemoglobin &lt; 9 g/dL ( NOTE : subject may receive growth factor blood transfusion within seven day hematologic laboratory value obtain Screening visit ) Total bilirubin ( TBL ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal Creatinine ( Cr ) &gt; 2 mg/dL Treatment androgen receptor antagonist ( bicalutamide , flutamide , nilutamide ) , 5α reductase inhibitor ( finasteride , dutasteride ) , estrogens , chemotherapy , biologic therapy within 4 week Day 1 visit Radiation therapy within 3 week ( single fraction radiotherapy within 2 week ) Day 1 visit , radionuclide therapy within 8 week Day 1 Planned palliative procedure alleviation bone pain radiation therapy surgery Structurally unstable bone lesion suggest impending fracture History seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumor , brain metastasis , alcoholism . Also , history loss consciousness transient ischemic attack within 12 month enrollment ( Day 1 visit ) Clinically significant cardiovascular disease include : Myocardial infarction within 6 month Screening visit ; Uncontrolled angina within 3 month Screening visit ; Congestive heart failure New York Heart Association ( NYHA ) class 3 4 , subject history congestive heart failure NYHA class 3 4 past , history anthracycline anthracenedione ( mitoxantrone ) treatment , unless screen echocardiogram multigated acquisition scan ( MUGA ) perform within three month Screening visit result leave ventricular ejection fraction ≥ 45 % History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsade de pointes ) Prolonged correct QT interval Fridericia correction formula ( QTcF ) Electrocardiogram ( ECG ) &gt; 470 msec . History Mobitz II second degree third degree heart block without permanent pacemaker place Hypotension ( systolic blood pressure &lt; 86 mmHg bradycardia heart rate &lt; 50 beat per minute ECG. , unless pharmaceutically induce thus reversible ( i.e . beta blocker ) . Uncontrolled hypertension indicate rest systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 105 mmHg Prior use ketoconazole , abiraterone acetate enzalutamide , participation previous clinical trial ketoconazole , abiraterone acetate enzalutamide History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Screening visit History GI bleed within 6 month Screening visit Active symptomatic viral hepatitis chronic liver disease Known history pituitary adrenal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>abiraterone acetate</keyword>
	<keyword>prednisone</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>MDV3100</keyword>
</DOC>